Study Summary
This trial is testing a new cancer drug, RBS2418, to see if it is effective at treating tumors. The drug works by increasing immunity and reducing adenosine production in tumors. This study is Phase 1a/1b, which means it is the first time the drug is being tested in humans. The study is open-label, meaning all participants will receive the drug, and it is multi-site, meaning it will take place at more than one location.
- Neoplasm Metastasis
- Cancer, Advanced
Treatment Effectiveness
Effectiveness Progress
Study Objectives
6 Primary · 1 Secondary · Reporting Duration: From 1- 21 days of the first cycle (each cycle is 21 days)
Trial Safety
Safety Progress
Trial Design
3 Treatment Groups
Treatment Group B
1 of 3
Treatment Group A-1
1 of 3
Treatment Group A-2
1 of 3
Experimental Treatment
64 Total Participants · 3 Treatment Groups
Primary Treatment: RBS2418 · No Placebo Group · Phase 1
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:About The Reviewer
Michael Gill - B. Sc.
First Published: October 7th, 2021
Last Reviewed: November 17th, 2022
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.
Who else is applying?
How old are they?
| 18 - 65 | 100.0% |
What site did they apply to?
| Tranquil Research | 100.0% |
What portion of applicants met pre-screening criteria?
| Met criteria | 100.0% |